<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To assess the effects of ACE-inhibition on insulin action in Type 2 (non-insulin-dependent) <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> associated with essential <z:hpo ids='HP_0000822'>hypertension</z:hpo>, 12 patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (on diet and oral hypoglycaemic agents) and arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> were examined on two occasions, in a single blind, cross-over study after two days of treatment with either <z:chebi fb="0" ids="3380">captopril</z:chebi> or a placebo </plain></SENT>
<SENT sid="1" pm="."><plain>The study consisted of a euglycaemic-hyperinsulinaemic clamp (two sequential steps of insulin infusion at the rates of 0.25 mU.kg-1.min-1 and 1 mU.kg-1.min-1, 2 h each step), combined with an infusion of 3-3H-<z:chebi fb="105" ids="17234">glucose</z:chebi> to measure the rate of hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production and that of peripheral <z:chebi fb="105" ids="17234">glucose</z:chebi> utilization </plain></SENT>
<SENT sid="2" pm="."><plain>The results show that blood pressure was lower after <z:chebi fb="0" ids="3380">captopril</z:chebi> (sitting, systolic 148 +/- 5 mm Hg, diastolic 89 +/- 2 mm Hg) compared to placebo (155 +/- 6 and 94 +/- 2 mm Hg) (p less than 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="3380">Captopril</z:chebi> treatment resulted in a more suppressed hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production (2.7 +/- 0.4 vs 4.94 +/- 0.55 mumol.kg-1.min-1), and a lower plasma non-esterified fatty acid concentration (0.143 +/- 0.05 vs 0.200 +/- 0.05 mmol/l) (<z:chebi fb="0" ids="3380">captopril</z:chebi> vs placebo, p less than 0.05) at the end of the first step of insulin infusion (estimated portal plasma insulin concentration 305 +/- 28 pmol/l); and in a greater <z:chebi fb="105" ids="17234">glucose</z:chebi> utilization (36.5 +/- 5.1 vs 28 +/- 3.6 mumol.kg-1.min-1, p less than 0.001) at the end of the second step of insulin infusion (arterial plasma insulin concentration of 604 +/- 33 pmol/l).(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>